ASSESSMENT OF NEPHRIN AND PODOCIN LEVELS IN THE URINE OF PATIENTS WITH DIABETES MELLITUS

THE AIM: to assess excretion value of podocytes injury biomarkers in urine and to clarify their significance for early diabetic nephropathy (DN) diagnostics in diabetes mellitus (DM) patients with different severity of albuminuria (AU)/proteinuria(PU). PATIENTS AND METHODS. 74 DM pts were studied, including 30 with type1 DM (T1DM) and 44 pts with type2 DM (T2DM). They were divided into three groups: 41 pts with AU <30 mg/gCr (A1), 13 pts with AU 30-300 mg/gCr (A2), 20 pts with PU (A3). CKD S1 was revealed in 41pts, CKD S2 – in 25 pts, CKD S3 – in 8 pts. Arterial hypertension was observed in 52 pts of 74(70%), mainly in T2DM. 10 healthy subjects were studied as control. Urinary levels of nephrin and podocin (an important slit diaphragm proteins) were measured by ELISA. RESULTS. Nephrinuria (NU) >5,84ng/ml/g, which not detecting in controls, was revealed in 63% of A1 pts, in 77% – in A2, in 80% – in A3. Podocinuria (PdU)>1,73ng/ml/g was revealed in 78% of A1 pts, in 54% of A2 and in 83% – A3. NU in pts with PU was significantly higher than in AU<30 mg/g. PDU in groups with different AU/PU was equally high and has no differ between DM types. Direct correlation was obtained between NU and AU (R=0,947 p<0,05). NU and PdU in T1DM correlated directly with serum creatinine (R=0,489 p<0,05 and R=0,468 p<0,05) and indirectly with GFR (R=-0,461 p<0,05 and R=-0,36 р<0,05). In DM duration less than 5 years NU directly correlated with НbА1с level, in T2DM – indirectly with systolic blood pressure. CONCLUSON. Nephrin and podocin levels can be useful for early diagnostics and monitoring of DN. 

1. International Diabetes Federation atlas (7th edition update). Brussels, Belgium. International Diabetes Federation; 2015. Available from: http://www.diabetesatlas.org/

2. Дедов ИИ, Шестакова МВ, Викулова ОК. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития. Сахарный диабет 2015; 18 (3): 5-22. DOI: 10.14341/DM201535-22 [Dedov II, Shestakova MV, Vikulova OK. Nacionalnyj registr saharnogo diabeta v Rossijskoj Federacii: status 2014 i perspectivy razvitija. Saharnyj Diabet 2015; 18(3): 5-22]

3. Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет 2016; 19(2): 104-112. DOI: 10.14341/DM2004116-17 [Dedov II, Shestakova MV, Galstjan GR. Rasprostranjonnost saharnogo diabeta 2 tipa u vzroslogo naselenija Rossii (issledovanie NATION). Saharnyj Diabet 2016; 19(2): 104-112]

4. Дедов ИИ. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике. Сахарный диабет 2010; 13(3): 6-13. DOI: 10.14341/2072-0351-5480 [Dedov II. Saharnyj diabet: razvitie tehnologij v diagnostike, lechenii i profilaktike. Saharnyj Diabet 2010; 13(3): 6-13]

5. Шестакова МВ, Шамхалова МШ, Ярек-Мартынова ИЯ и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет 2011; 14(1): 81-88. DOI:0.14341/2072-03516254 [Shestakova MV, Shamhalova Msh, Jarek-Martynova IYa i dr. Saharnyj diabet i hronicheskaja bolezn pochek: dostizhenija, nereshennye problemy i perspectivy lechenija. Saharnyj Diabet 2011; 14(1): 81-88]

6. Shestakova M, Mukhin N, Dedov I et al. Protein-loading test, urinary albumin excretion and renal morphology in diagnosis of subclinical diabetic nephropathy. J Int Med 1992, 231 (3): 213- 217

7. Dalla Vestra M, Saller A, Bortoloso E et al. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26 (4): 8-14. DOI: 10.2337/diabetes.52.4.1031

8. Смирнов АВ, Добронравов ВА, Кисина АА и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология 2015; 19(1): 67-77. DOI [313.053036.865+613.693]-08.847 [Smirnov AV, Dobronravov VA, Kisina AA i dr. Klinicheskije recomendacii po diagnostice i lecheniju diabeticheskoj nefropatii. Nefrologia 2015; 19(1): 67-77]

9. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60 (5):850-886

10. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Intern 2013; 3: 1-150

11. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83(1): 253-307. DOI: 10.1152/physrev.00020.2002

12. Barisoni L, Kopp JB. Update in podocyte biology: putting one’s best foot forward. Curr Opin Nephrol Hypertens 2003; 12(3): 251-258. DOI: 10.1097/01.mnh.0000069861.94246.8c

13. Shankland SJ. The podocyte′s response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 2006: 69; 21312147. DOI: 10.1038/sj.ki.5000410

14. Kriz W, Elger M, Nagata M et al. The role of podocytes in the development of glomerular sclerosis. Kidney Int 1994: suppl 45; S64-S72

15. Бобкова ИН, Шестакова МВ, Щукина АА. Диабетическая нефропатия – фокус на повреждение подоцитов. Нефрология 2015; 2 (19): 33-44 [Bobkova IN, Shestakova MV, Schukina AA. Diabeticheskaja nefropatija –fokus na povrezhdenie podocytov. Nefrologija 2015; 2 (19): 33-44]

16. Granier C, Makni K, Molina L. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 7922799. DOI: 10.1093/ndt/gfm834

17. Ziyadeh FN, Wolf G. Pathogenesis of podocytopathy and proteiuria in diabetic glomerulopathy. Current Diabetes Reviews 2008; 4: 39-45. DOI: 10.2174/157339908783502370

18. Wolf G, Chen S, Ziyadeh FN. From the periphery of glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54(6): 1626-1634. DOI.org/10.2337/diabetes.54.6.1626

19. Stitt-Cavanagh E, MacLeod L, Kennedy CRJ. The podocyte in diabetic kidney disease. The Scientific World Journal 2009; 9:1127-1139. DOI: 10.1100/tsw.2009.133

20. Reddy GR, Kotlyarevska K, Ransom RF. The podocyte and diabetes mellitus: is the podocyte key to the origins of diabetic nephropathy? Сurr Opin Nephrol Hypertens 2008; 17: 32-36. DOI: 10.1097/MNH.0b013e3282f2904d

21. Steffes MW, Schmidt D, McGregory R, Basgen JM. Glomerular cell number in normal subject and in type 1diabetic patients. Kidney Int 2001; 59: 2104-2113. DOI: 10.1046/j.15231755.2001.00725.x

22. Patari A, Forsblom C, Havana et al. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003; 52: 2969-2974. DOI: 10.2337/diabetes.52.12.2969

23. Jim B, Ghanta M, Qipo A et al. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross Sectional study. PLoS ONE 2012; 7(5): e36041. DOI: 10.1371/journal.pone.0036041

24. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Current Diabetes Review 2005; 1(1): 27-40

25. Stitt-Cavanagh E, MacLeod L, Kennedy CRJ. The podocyte in diabetic kidney disease. Scientific World Journal 2009; 9: 1127–1139. DOI: 10.1100/tsw.2009.133

26. Cooper ME. Interaction of metabolic and haemodinamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972. DOI: 10.1007/s001250100000

27. Wang G, Lai FM, Kwan BC et al. Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens 2009; 22: 300-306. DOI: 10.1038/ajh.2008.360

28. Forbes JM, Bonnet F, Russo LM et al. Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J of Hypertension 2002; 20(5): 985-992

29. Amazonas RB, de Almedia Sanita R, Kawashi H et al. Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus. Nephron Physiol 2007; 107; 57-64

30. Lewko B, Stepinski J. Hypergliycemia and mechanical stress: Targeting the renal podocyte. J Cell Physiol 2009; 221(2): 288-295. DOI: 10.1002/jcp.21856

31. Jia J, Ding G, Zhu J et al. Angiotensin II infusion induced nephrin expression changes and podocyte apoptosis. Am J Nephrol 2008; 28 (3): 500-507. DOI: 10.1159/000113538

32. Abbate M, Zoja C, Morigi M et al. Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161(6): 2179–2193. doi: 10.1016/S0002-9440(10)64495-1

33. Durvasula RV, Petermann AT, Hiromura K et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65(1): 30–39. DOI: 10.1111/j.15231755.2004.00362.x

34. Li Y, Kang YS, Dai C et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172(2): 299–308. DOI: 10.2353/ ajpath.2008.070057 35. Liu Y. New Insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222. DOI: 10.1681/ASN.2008121226